Investment Thesis
Bolt Biotherapeutics is a pre-revenue biotech company with $26K in annual revenue, burning $8M in operating cash flow annually against only $11.6M in cash reserves—implying ~1.4 years of runway at current burn rate. Without demonstrated commercial products or significant revenue, the company faces critical funding risk and lacks fundamental operational viability in its current form.
Strengths
- Zero debt structure provides financial flexibility and eliminates interest burden
- Strong current ratio of 3.51x indicates adequate short-term liquidity to meet obligations
- Minimal capital expenditure of $72K demonstrates lean operational footprint
Risks
- Near-zero revenue of $26K provides no commercial validation or cash generation
- Operating cash burn of $8M annually against $11.6M cash reserves creates critical funding timeline
- Massive operating losses with -29,234.6% operating margin indicate unsustainable business model
- Limited cash runway (~1.4 years) without external funding or revenue inflection
- Zero Form 4 insider filings in 90 days suggests no management confidence demonstrated through transactions
Key Metrics to Watch
- Cash burn rate and months of cash runway remaining
- Revenue growth rate and timing of product commercialization
- Operating cash flow trajectory and path to cash flow breakeven
Financial Metrics
Revenue
26.0K
Net Income
-7.2M
EPS (Diluted)
$-4.31
Free Cash Flow
-8.1M
Total Assets
48.0M
Cash
11.6M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-29,234.6%
Net Margin
-27,861.5%
ROE
-36.5%
ROA
-15.1%
FCF Margin
-31,134.6%
Balance Sheet & Liquidity
Current Ratio
3.51x
Quick Ratio
3.51x
Debt/Equity
0.00x
Debt/Assets
58.7%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-13T07:59:50.813268 |
Data as of: 2026-03-31 |
Powered by Claude AI